

APPROVED
BY OIPE JC132
CLASS CLASS
FEB 27 2003
PATENT & TRADEMARK OFFICE

1/51




FIG.1A





FIG.1B



2/51




FIG.1C




FIG.1D

FEB 27 2003
PATENT & TRADEMARK OFFICE

3/51





FIG.1E




FIG.2B




FIG.2A




FIG.2D









FIG.2C



6/51





7/51

FIG.3C









FIG.3D



8/51





9/51

FIG.3G






FIG.3H





10/51

FIG.3I





FIG.3J






FIG.4B





FIG.4A



13/51




FIG.5A




FIG.5B





FIG.5C



14/51




FIG.6A




FIG. 6B



FIG. 6C




FIG. 6D




FIG. 6E

16/51




FIG. 6F




FIG. 6G




FIG. 6H

17/51






FIG. 7B

FIG. 7A



18/51






FIG.7C



539

FIG. 8A

FIG. 8B

FIG. 8




FIG. 9A





FIG. 9B



22/51

↓ hCG




FIG.10A




FIG.10B





FIG.10C



23/51




FIG.10D




FIG.10E





FIG.10F



24/51





FIG.11



25/51

FIG.12A




FIG.12B






FIG.12C





26/51




FIG.13



27/51





FIG.14

28/51



29/51





FIG.15B



30/51

VIRAL LOAD VERSUS HAF DOSE






FIG.15C



31/51




FIG.16A




FIG.16B





FIG.17A



COLLECTED: 1/28/97 8:06 PM

MIRROR RATIO: 1.060
PSD MIRROR RATIO:
TIMED ION SELECTOR: 15.5 OFF
NEGATIVE IONS: OFF

LASER: 2600
SCANS AVERAGED: 52
PRESSURE: 4.64e-07
LOW MASS GATE: 500.0

ACCELERATING VOLTAGE: 25000
GRID VOLTAGE: 88.000 %
GUIDE WIRE VOLTAGE: 0.200 %
DELAY: 300 ON

METHOD: PRO60K_L
MODE: LINEAR





FIG.17B



COLLECTED: 1/28/97 8:11 PM

MIRROR RATIO: 1.060
PSD MIRROR RATIO:
TIMED ION SELECTOR: 15.5 OFF
NEGATIVE IONS: OFF

LASER: 2700
SCANS AVERAGED: 90
PRESSURE: 3.40e-07
LOW MASS GATE: 500.0

ACCELERATING VOLTAGE: 25000
GRID VOLTAGE: 88.000 %
GUIDE WIRE VOLTAGE: 0.200 %
DELAY: 300 ON

METHOD: PRO60K_L
MODE: LINEAR





FIG.17C



METHOD: PRO60K_L	ACCELERATING VOLTAGE: 25000	LASER: 2408	MIRROR RATIO: 1.060
MODE: LINEAR	GRID VOLTAGE: 88.000 %	SCANS AVERAGED: 125	PSD MIRROR RATIO:
	GUIDE WIRE VOLTAGE: 0.200 %	PRESSURE: 3.12e-07	TIMED ION SELECTOR: 15.5 OFF
	DELAY: 300 ON	LOW MASS GATE: 500.0	NEGATIVE IONS: OFF





FIG.17D



METHOD: PRO60K_L
MODE: LINEAR

ACCELERATING VOLTAGE: 25000
GRID VOLTAGE: 88.000 %
GUIDE WIRE VOLTAGE: 0.200 %
DELAY: 300 ON

LASER: 2700
SCANS AVERAGED: 57
PRESSURE: 3.02e-07
LOW MASS GATE: 500.0

MIRROR RATIO: 1.060
PSD MIRROR RATIO:
TIMED ION SELECTOR: 15.5 OFF
NEGATIVE IONS: OFF





FIG.17E



METHOD: PRO60K_L
MODE: LINEAR

ACCELERATING VOLTAGE: 25000
GRID VOLTAGE: 88.000 %
GUIDE WIRE VOLTAGE: 0.200 %
DELAY: 300 ON

LASER: 2700
SCANS AVERAGED: 45
PRESSURE: 2.87e-07
LOW MASS GATE: 500.0

MIRROR RATIO: 1.060
PSD MIRROR RATIO:
TIMED ION SELECTOR: 15.5 OFF
NEGATIVE IONS: OFF



FIG.18A




FIG.18B




FIG.18C

38/51




FIG. 18D



FIG. 18E



FIG. 18F

02/27/03
jc914 U.S. PTO

39/51




FIG. 18G





FIG. 18H



40/51
INHIBITION IN %

FIG.19



02/27/03



914 U.S. PTO

41/51



FIG.20A



FIG.20B





FIG.20C



42/51





FIG.21



43/51





FIG.22A



44/51




FIG.22B



45/51





FIG.22C

46/51




FIG. 23A




FIG. 23B

APPROVED

D. C. FIG.

02/27/03

1c914 U.S. PTO

47/51




FIG.23C



FIG.23D

48/51



FIG.23E




FIG.23F

49/51




FIG.24A




FIG.24B



FIG.24C

APPROVED	O.G. FIG.	
BY	CLASS	SUBCLASS

02/27/03

1c914 U.S. PTO

50/51




FIG. 24D




FIG. 24E



FIG 24F

APPROVED	O.G. FIG.	
CLASS	SUBCLASS	

02/27/03

10914 U.S. PTO

51/51




FIG.24G



FIG.24H



FIG.24I